Table of Contents: 1 Executive Summary 1.1 Market Attractiveness Analysis 2 Market Introduction 2.1 Definition 2.2 Scope of the Study 2.3 Assumptions 2.4 Market Structure 3 Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 3.4 Market Size Estimation 3.5 Forecast Model 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 Worldwide Rising Prevalence of Asthma, Bronchospasm, Allergic Rhinitis, and Urticaria 4.2.2 Burgeoning Pharmaceutical Industry Coupled with the Growing Demand from API Manufacturers 4.2.3 Montelukast Patent Expiration Along with the Increasing Presence of Generics 4.3 Restraints 4.3.1 Presence of Stringent Regulatory Policies 4.3.2 High Cost of Manufacturing Building Blocks for APIs 4.4 Opportunity 4.4.1 Ongoing Research and Development Activities 5 Market Factor Analysis 5.1 Value Chain Analysis 5.1.1 Raw Material Sourcing 5.1.2 Manufacturing 5.1.3 Distribution & Sales 5.1.4 End Users 5.2 Supply Chain Analysis 5.2.1 Raw Material Manufacturer 5.2.2 Montelukast Intermediate Manufacturer 5.2.3 Importer 5.2.4 Distributors 5.2.5 Final Product Manufacturer/Customer 5.3 Porter’s Five Forces Model 5.3.1 Threat of New Entrants 5.3.2 Bargaining Power of Suppliers 5.3.3 Bargaining Power of Buyers 5.3.4 Threat of Substitutes 5.3.5 Intensity of Rivalry 5.4 Investment Opportunities 5.5 Pricing Analysis 5.6 Clinical Trials 5.6.1 Overview 5.7 Patent Analysis 5.8 Key Customers 5.9 Regulatory Scenario 5.1 Pricing Evolution 5.11 Manufacturing Processes 5.11.1 Biological Method 5.11.2 Chemical Method 5.12 Specifications and Purity Requirement 6 Global Montelukast Intermediate Market, By Application 6.1 Overview 6.2 Asthma 6.3 Allergic Rhinitis 6.4 Bronchospasm 6.5 Urticaria 7 Global Montelukast Intermediate Market, by Region 7.1 Overview 7.2 Americas 7.2.1 North America 7.2.1.1 US 7.2.1.2 Canada 7.2.2 Latin America 7.3 Europe 7.3.1 Western Europe 7.3.1.1 UK 7.3.1.2 France 7.3.1.3 Spain 7.3.1.4 Germany 7.3.1.5 Italy 7.3.1.6 Rest of Western Europe 7.3.2 Eastern Europe 7.4 Asia-Pacific 7.4.1 China 7.4.2 India 7.4.3 Japan 7.4.4 Rest of Asia-Pacific 7.5 Middle East & Africa 7.5.1 Middle East 7.5.2 Africa 8 Competitive Landscape 8.1 Introduction 8.2 Major Players in the Global Montelukast Intermediate Market 9 Company Profiles 9.1 VIVAN Life Sciences 9.1.1 Financial Overview 9.1.2 Products/Services Offered 9.1.3 Key Developments 9.1.4 SWOT Analysis 9.1.5 Key Strategies 9.2 P.G. Shah & Co. 9.2.1 Company Overview 9.2.2 Financial Overview 9.2.3 Products/Services Offered 9.2.4 Key Developments 9.2.5 SWOT Analysis 9.2.6 Key Strategies 9.3 Manus Aktteva Biopharma LLP 9.3.1 Company Overview 9.3.2 Financial Overview 9.3.3 Products/Services Offered 9.3.4 Key Developments 9.3.5 SWOT Analysis 9.3.6 Key Strategies 9.4 Ortin Laboratories Limited 9.4.1 Company Overview 9.4.2 Financial Overview 9.4.3 Products/Services Offered 9.4.4 Key Developments 9.4.5 SWOT Analysis 9.4.6 Key Strategies 10 Appendix 10.1 References 10.2 Related Reports

List of Tables: TABLE 1 CLINICAL TRIALS TABLE 2 PRICING RANGE FOR MONTELUKAST INTERMEDIATE (USD/KG) TABLE 3 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 4 GLOBAL MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2015–2023 (KG) TABLE 5 GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR ASTHMA, BY REGION, 2015–2023 (USD THOUSAND) TABLE 6 GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR ALLERGIC RHINITIS, BY REGION, 2015–2023 (USD THOUSAND) TABLE 7 GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR BRONCHOSPASM, BY REGION, 2015–2023 (USD THOUSAND) TABLE 8 GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR URTICARIA, BY REGION, 2015–2023 (USD THOUSAND) TABLE 9 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2015–2023 (USD THOUSAND) TABLE 10 GLOBAL: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY REGION, 2015–2023 (KG) TABLE 11 AMERICAS: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2015–2023 (USD THOUSAND) TABLE 12 AMERICAS: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY REGION, 2015–2023 (KG) TABLE 13 AMERICAS: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 14 AMERICAS: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2015–2023 (KG) TABLE 15 NORTH AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND) TABLE 16 NORTH AMERICA: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY COUNTRY, 2015–2023 (KG) TABLE 17 NORTH AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 18 US: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 19 CANADA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 20 LATIN AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 21 EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2015–2023 (USD THOUSAND) TABLE 22 EUROPE: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY REGION, 2015–2023 (KG) TABLE 23 EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 24 EUROPE: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2015–2023 (KG) TABLE 25 WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND) TABLE 26 WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY COUNTRY, 2015–2023 (KG) TABLE 27 WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 28 UK: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 29 FRANCE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 30 SPAIN: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 31 GERMANY: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 32 ITALY: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 33 REST OF WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 34 EASTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 35 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND) TABLE 36 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY COUNTRY, 2015–2023 (KG) TABLE 37 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 38 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2015–2023 (KG) TABLE 39 CHINA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 40 INDIA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 41 JAPAN: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 42 REST OF ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 43 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2015–2023 (USD THOUSAND) TABLE 44 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY COUNTRY, 2015–2023 (KG) TABLE 45 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 46 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2015–2023 (KG) TABLE 47 MIDDLE EAST: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND) TABLE 48 MIDDLE EAST: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2015–2023 (USD THOUSAND)List of Figures: FIGURE 1 MARKET SYNOPSIS FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL MONTELUKAST INTERMEDIATE MARKET FIGURE 3 GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY APPLICATION, 2017 (%) FIGURE 4 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2016–2023 (USD THOUSANDS) FIGURE 5 GLOBAL MONTELUKAST INTERMEDIATE MARKET: MARKET STRUCTURE FIGURE 6 RESEARCH PROCESS OF MRFR FIGURE 7 TOP-DOWN & BOTTOM-UP APPROACH FIGURE 8 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MONTELUKAST INTERMEDIATE MARKET FIGURE 9 VALUE CHAIN: GLOBAL MONTELUKAST INTERMEDIATE MARKET FIGURE 10 SUPPLY/VALUE CHAIN: GLOBAL MONTELUKAST INTERMEDIATE MARKET FIGURE 11 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL MONTELUKAST INTERMEDIATE MARKET FIGURE 12 PROCESS 1 FIGURE 13 PROCESS 2 FIGURE 14 PROCESS 3 FIGURE 15 PROCESS 4 FIGURE 16 PROCESS 5 FIGURE 17 GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY APPLICATION, 2017 (%) FIGURE 18 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2017 & 2023 (USD THOUSAND) FIGURE 19 GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2017 (%) FIGURE 20 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2017 & 2023 (USD THOUSAND) FIGURE 21 AMERICAS: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2017 (%) FIGURE 22 EUROPE: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2017 (%) FIGURE 23 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET SHARE, BY COUNTRY, 2017 (%) FIGURE 24 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2017 (%)

P.G. Shah & Co., Manus Aktteva Biopharma LLP, VIVAN Life Sciences, P.G. Shah & Co. and Ortin Laboratories Limited.